Cancer‐on‐a‐Chip for Modeling Immune Checkpoint Inhibitor and Tumor Interactions

Cancer immunotherapies, including immune checkpoint inhibitor (ICI)‐based therapies, have revolutionized cancer treatment. However, patient response to ICIs is highly variable, necessitating the development of methods to quickly assess efficacy. In this study, an array of miniaturized bioreactors ha...

Full description

Saved in:
Bibliographic Details
Published in:Small (Weinheim an der Bergstrasse, Germany) Germany), 2021-02, Vol.17 (7), p.e2004282-n/a
Main Authors: Jiang, Xing, Ren, Li, Tebon, Peyton, Wang, Canran, Zhou, Xingwu, Qu, Moyuan, Zhu, Jixiang, Ling, Haonan, Zhang, Shiming, Xue, Yumeng, Wu, Qingzhi, Bandaru, Praveen, Lee, Junmin, Kim, Han‐Jun, Ahadian, Samad, Ashammakhi, Nureddin, Dokmeci, Mehmet R., Wu, Jinhui, Gu, Zhen, Sun, Wujin, Khademhosseini, Ali
Format: Article
Language:English
Subjects:
Antibodies
Arrays
Bioreactors
Cancer
cancer immunotherapy
cancer‐on‐a‐chip
drug screening
high‐throughput observation chamber
Humans
Immune Checkpoint Inhibitors
Immunotherapy
Inhibitors
Interleukins
Lab-On-A-Chip Devices
Lymphocytes
Nanotechnology
Neoplasms - drug therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer immunotherapies, including immune checkpoint inhibitor (ICI)‐based therapies, have revolutionized cancer treatment. However, patient response to ICIs is highly variable, necessitating the development of methods to quickly assess efficacy. In this study, an array of miniaturized bioreactors has been developed to model tumor‐immune interactions. This immunotherapeutic high‐throughput observation chamber (iHOC) is designed to test the effect of anti‐PD‐1 antibodies on cancer spheroid (MDA‐MB‐231, PD‐L1+) and T cell (Jurkat) interactions. This system facilitates facile monitoring of T cell inhibition and reactivation using metrics such as tumor infiltration and interleukin‐2 (IL‐2) secretion. Status of the tumor‐immune interactions can be easily captured within the iHOC by measuring IL‐2 concentration using a micropillar array where sensitive, quantitative detection is allowed after antibody coating on the surface of array. The iHOC is a platform that can be used to model and monitor cancer‐immune interactions in response to immunotherapy in a high‐throughput manner. Patient responses to immune checkpoint inhibitor (ICI)‐based therapies are highly variable, calling for a rapid evaluation approach. Here, a cancer‐on‐a‐chip platform is designed to monitor ICI‐associated cancer‐immune interactions between cancer spheroids and T cells in a high‐throughput manner. The system is a promising screening platform for drug discovery, drug safety assessment, and personalized medicine.
ISSN:1613-6810
1613-6829
DOI:10.1002/smll.202004282